Anti-inflammatory potential of Empagliflozin

doi:10.1007/s10787-021-00797-9

. 2021 Apr;29(2):573-576.

doi: 10.1007/s10787-021-00797-9. Epub 2021 Mar 17.

Anti-inflammatory potential of Empagliflozin

Markus Pirklbauer¹

Affiliations

Affiliation

¹ Department of Internal Medicine IV-Nephrology and Hypertension, Medical University Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. markus.pirklbauer@i-med.ac.at.

PMID: 33728540
PMCID: PMC7997819
DOI: 10.1007/s10787-021-00797-9

Anti-inflammatory potential of Empagliflozin

Markus Pirklbauer. Inflammopharmacology. 2021 Apr.

. 2021 Apr;29(2):573-576.

doi: 10.1007/s10787-021-00797-9. Epub 2021 Mar 17.

Author

Markus Pirklbauer¹

Affiliation

¹ Department of Internal Medicine IV-Nephrology and Hypertension, Medical University Innsbruck, Anichstrasse 35, 6020, Innsbruck, Austria. markus.pirklbauer@i-med.ac.at.

PMID: 33728540
PMCID: PMC7997819
DOI: 10.1007/s10787-021-00797-9

No abstract available

Keywords: Anti-inflammatory potential; Empagliflozin; Human proximal tubulus; Nephroprotection; SGLT2 inhibition.

PubMed Disclaimer

Conflict of interest statement

The author declares that he has no competing interests.

Cited by

Beneficial Effects of Empagliflozin Are Mediated by Reduced Renal Inflammation and Oxidative Stress in Spontaneously Hypertensive Rats Expressing Human C-Reactive Protein.
Malínská H, Hüttl M, Marková I, Miklánková D, Hojná S, Papoušek F, Šilhavý J, Mlejnek P, Zicha J, Hrdlička J, Pravenec M, Vaněčková I. Malínská H, et al. Biomedicines. 2022 Aug 24;10(9):2066. doi: 10.3390/biomedicines10092066. Biomedicines. 2022. PMID: 36140169 Free PMC article.
Empagliflozin-Metformin Combination Has Antioxidative and Anti-Inflammatory Properties that Correlate with Vascular Protection in Adults with Type 1 Diabetes.
Janić M, Cankar M, Šmid J, France Štiglic A, Jerin A, Šabovič M, Janež A, Lunder M. Janić M, et al. J Diabetes Res. 2022 May 17;2022:6796470. doi: 10.1155/2022/6796470. eCollection 2022. J Diabetes Res. 2022. PMID: 35620570 Free PMC article. Clinical Trial.
Evaluation of the effect of empagliflozin on prevention of atrial fibrillation after coronary artery bypass grafting: a double-blind, randomized, placebo-controlled trial.
Zarei B, Fazli B, Tayyebi M, Abbasi Teshnizi M, Moeinipour A, Javedanfar O, Javidi Dasht Bayaz R, Rahmati M, Ghavami V, Amini S, Mohammadpour AH. Zarei B, et al. Naunyn Schmiedebergs Arch Pharmacol. 2024 Dec;397(12):9935-9946. doi: 10.1007/s00210-024-03225-1. Epub 2024 Jul 2. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38953969 Clinical Trial.
Looking deeper into the findings of DARE-19: Failure or an open door to future success?
Koufakis T, Maltese G, Metallidis S, Zebekakis P, Kotsa K. Koufakis T, et al. Pharmacol Res. 2021 Nov;173:105872. doi: 10.1016/j.phrs.2021.105872. Epub 2021 Sep 4. Pharmacol Res. 2021. PMID: 34487851 Free PMC article. No abstract available.
Inflammatory setting, therapeutic strategies targeting some pro-inflammatory cytokines and pathways in mitigating ischemia/reperfusion-induced hepatic injury: a comprehensive review.
Aboelez MO, Ezelarab HAA, Alotaibi G, Abouzed DEE. Aboelez MO, et al. Naunyn Schmiedebergs Arch Pharmacol. 2024 Sep;397(9):6299-6315. doi: 10.1007/s00210-024-03074-y. Epub 2024 Apr 21. Naunyn Schmiedebergs Arch Pharmacol. 2024. PMID: 38643452 Review.

See all "Cited by" articles

References

1. Anders HJ. Of inflammasomes and alarmins: IL-1β and IL-1α in kidney disease. J Am Soc Nephrol. 2016;27:2564–2575. doi: 10.1681/ASN.2016020177. - DOI - PMC - PubMed
1. Anders HJ, Huber TB, Isermann B, Schiffer M. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol. 2018;14:361–377. doi: 10.1038/s41581-018-0001-y. - DOI - PubMed
1. Benetti E, Mastrocola R, Vitarelli G, Cutrin JC, Nigro D, Chiazza F, Mayoux E, Collino M, Fantozzi R. Empagliflozin protects against diet-induced NLRP-3 inflammasome activation and lipid accumulation. J Pharmacol Exp Ther. 2016;359:45–53. doi: 10.1124/jpet.116.235069. - DOI - PubMed
1. Boels MGS, Koudijs A, Avramut MC, Sol WMPJ, Wang G, van Oeveren-Rietdijk AM, van Zonneveld AJ, de Boer HC, van der Vlag J, van Kooten C, Eulberg D, van den Berg BM, IJpelaar DHT, Rabelink TJ (2017) Systemic monocyte chemotactic protein-1 inhibition modifies renal macrophages and restores glomerular endothelial glycocalyx and barrier function in diabetic nephropathy. Am J Pathol 187:2430–2440 - PubMed
1. Byrne NJ, Matsumura N, Maayah ZH, Ferdaoussi M, Takahara S, Darwesh AM, Levasseur JL, Jahng JWS, Vos D, Parajuli N, El-Kadi AOS, Braam B, Young ME, Verma S, Light PE, Sweeney G, Seubert JM, Dyck JRB. Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (nucleotide-binding domain-like receptor protein 3) inflammasome activation in heart failure. Circ Heart Fail. 2020;13:e006277. - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Europe PubMed Central
- PubMed Central
Other Literature Sources
- scite Smart Citations

[1] Anders HJ. Of inflammasomes and alarmins: IL-1β and IL-1α in kidney disease. J Am Soc Nephrol. 2016;27:2564–2575. doi: 10.1681/ASN.2016020177. - DOI - PMC - PubMed

[2] Anders HJ. Of inflammasomes and alarmins: IL-1β and IL-1α in kidney disease. J Am Soc Nephrol. 2016;27:2564–2575. doi: 10.1681/ASN.2016020177. - DOI - PMC - PubMed

[3] Anders HJ, Huber TB, Isermann B, Schiffer M. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol. 2018;14:361–377. doi: 10.1038/s41581-018-0001-y. - DOI - PubMed

[4] Anders HJ, Huber TB, Isermann B, Schiffer M. CKD in diabetes: diabetic kidney disease versus nondiabetic kidney disease. Nat Rev Nephrol. 2018;14:361–377. doi: 10.1038/s41581-018-0001-y. - DOI - PubMed

[5] Benetti E, Mastrocola R, Vitarelli G, Cutrin JC, Nigro D, Chiazza F, Mayoux E, Collino M, Fantozzi R. Empagliflozin protects against diet-induced NLRP-3 inflammasome activation and lipid accumulation. J Pharmacol Exp Ther. 2016;359:45–53. doi: 10.1124/jpet.116.235069. - DOI - PubMed

[6] Benetti E, Mastrocola R, Vitarelli G, Cutrin JC, Nigro D, Chiazza F, Mayoux E, Collino M, Fantozzi R. Empagliflozin protects against diet-induced NLRP-3 inflammasome activation and lipid accumulation. J Pharmacol Exp Ther. 2016;359:45–53. doi: 10.1124/jpet.116.235069. - DOI - PubMed

[7] Boels MGS, Koudijs A, Avramut MC, Sol WMPJ, Wang G, van Oeveren-Rietdijk AM, van Zonneveld AJ, de Boer HC, van der Vlag J, van Kooten C, Eulberg D, van den Berg BM, IJpelaar DHT, Rabelink TJ (2017) Systemic monocyte chemotactic protein-1 inhibition modifies renal macrophages and restores glomerular endothelial glycocalyx and barrier function in diabetic nephropathy. Am J Pathol 187:2430–2440 - PubMed

[8] Boels MGS, Koudijs A, Avramut MC, Sol WMPJ, Wang G, van Oeveren-Rietdijk AM, van Zonneveld AJ, de Boer HC, van der Vlag J, van Kooten C, Eulberg D, van den Berg BM, IJpelaar DHT, Rabelink TJ (2017) Systemic monocyte chemotactic protein-1 inhibition modifies renal macrophages and restores glomerular endothelial glycocalyx and barrier function in diabetic nephropathy. Am J Pathol 187:2430–2440 - PubMed

[9] Byrne NJ, Matsumura N, Maayah ZH, Ferdaoussi M, Takahara S, Darwesh AM, Levasseur JL, Jahng JWS, Vos D, Parajuli N, El-Kadi AOS, Braam B, Young ME, Verma S, Light PE, Sweeney G, Seubert JM, Dyck JRB. Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (nucleotide-binding domain-like receptor protein 3) inflammasome activation in heart failure. Circ Heart Fail. 2020;13:e006277. - PubMed

[10] Byrne NJ, Matsumura N, Maayah ZH, Ferdaoussi M, Takahara S, Darwesh AM, Levasseur JL, Jahng JWS, Vos D, Parajuli N, El-Kadi AOS, Braam B, Young ME, Verma S, Light PE, Sweeney G, Seubert JM, Dyck JRB. Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (nucleotide-binding domain-like receptor protein 3) inflammasome activation in heart failure. Circ Heart Fail. 2020;13:e006277. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Anti-inflammatory potential of Empagliflozin

Affiliation

Anti-inflammatory potential of Empagliflozin

Author

Affiliation

Conflict of interest statement

Similar articles

Cited by

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Conflict of interest statement

Similar articles

Cited by

References

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Other Literature Sources